Does Cigna Cover GLP-1 Weight Loss Drugs? Honest Coverage Review

Short version: Cigna runs its pharmacy benefit through Express Scripts / Evernorth, its own PBM. GLP-1s for type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus) are widely covered with prior authorization. GLP-1s for chronic weight management (Wegovy, Zepbound, Saxenda) are excluded from the standard Express Scripts National Preferred Formulary and are only covered when an employer specifically buys anti-obesity-medication (AOM) coverage as a benefit option. When covered, Cigna applies a strict prior-authorization gate: BMI thresholds, a trial of at least two oral weight-loss drugs, a comprehensive weight-management program, and quantity limits.^[1] Cigna Medicare plans cannot cover weight-loss-only GLP-1s under federal Part D — but the new Medicare GLP-1 Bridge demonstration (July 1, 2026) and the Zepbound-OSA / Wegovy-CV carve-ins change that picture.^[2][9] Because the formulary is really an Express Scripts formulary, see our dedicated guide on does Express Scripts cover weight-loss drugs.

At a glance

• Cigna GLP-1 coverage for type 2 diabetes: generally YES with prior authorization. Ozempic, Mounjaro, Trulicity, Victoza, and Rybelsus are on most Cigna/Express Scripts commercial formularies for the diabetes indication.^[4]
• Cigna GLP-1 coverage for chronic weight management: only when your employer buys it. Wegovy and Zepbound are excluded from the standard Express Scripts National Preferred Formulary; AOM coverage is an employer add-on, not a default benefit.^[4]
• When covered, the PA bar is strict: BMI ≥ 30, OR BMI ≥ 27 with a weight-related comorbidity (or established CVD); age 18+; an inadequate response/intolerance/contraindication to at least two oral weight-loss medications; participation in a comprehensive weight-management program; and a preferred-product step-therapy requirement.^[1]
• Evernorth $200/month cap: for participating employer plans, Evernorth caps member out-of-pocket on Wegovy and Zepbound at $200/month (launched May 21, 2025), and the amount counts toward the annual deductible.^[5] This sits on top of the EncircleRx weight-management program (>9 million enrolled lives).^[5]
• Cigna Medicare (Part D): NO for weight-loss-only Wegovy/Zepbound/Saxenda under federal Social Security Act §1860D-2(e)(2)(A).^[2] YES for Zepbound OSA (post-12/20/2024) and Wegovy cardiovascular risk reduction.^[6][7]
• Medicare GLP-1 Bridge (new): a CMS demonstration running July 1, 2026 – December 31, 2027 lets eligible Part D members get GLP-1s for weight management at a flat $50/month copay, regardless of whether their Part D plan opts in.^[9]
• Cost when covered: Express Scripts typically places weight-loss GLP-1s on a non-preferred brand tier with PA. Out-of-pocket is plan-specific; the Evernorth-cap option lands at up to $200/month.^[5]

Cigna runs its pharmacy benefit through Express Scripts / Evernorth

Cigna does not administer its prescription-drug benefit in-house. Cigna's pharmacy benefit manager is Express Scripts, and both Cigna's health-services arm and Express Scripts sit under the Evernorth umbrella. That means three things flow through Express Scripts/Evernorth rather than through Cigna's medical side: the formulary (which drugs are covered and on which tier), prior-authorization adjudication, and step-therapy and quantity-limit rules.^[4]

Practically, that matters because the single most important variable for a weight-loss GLP-1 is which formulary your employer chose:

• Express Scripts National Preferred Formulary (NPF) — the standard book of business. Weight-loss GLP-1s (Wegovy, Zepbound, Saxenda) are excluded from the base NPF as anti-obesity medications.^[4] Diabetes GLP-1s remain covered.
• Custom employer formularies with an AOM benefit. Large employers can buy weight-loss-drug coverage as an add-on. Many of these run through Evernorth's weight-management benefit option that caps member cost at $200/month.^[5]
• Accredo — Evernorth's specialty pharmacy. Some Cigna plans route GLP-1 fills (and the PA paperwork) through Accredo or the Express Scripts/EnGuide home-delivery pharmacy rather than retail.^[5]

So the question “does Cigna cover Wegovy” is really “did my employer add AOM coverage to its Express Scripts plan, and does my plan use the $200-cap benefit option?” Two Cigna members with identical diagnoses can get opposite answers based purely on employer plan design.

GLP-1 coverage for type 2 diabetes (widely covered)

On Cigna/Express Scripts commercial plans, GLP-1 receptor agonists for the type 2 diabetes indication are generally on-formulary with prior authorization. The agents commonly covered:

• Ozempic (semaglutide) — once-weekly injection, FDA-approved for T2D + cardiovascular risk reduction in T2D with established CVD.
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1, FDA-approved for T2D.
• Trulicity (dulaglutide) — once-weekly GLP-1, FDA-approved for T2D + CV risk reduction.
• Victoza (liraglutide) — daily GLP-1, FDA-approved for T2D; older agent with both branded and authorized-generic forms.
• Rybelsus (oral semaglutide) — daily oral tablet, FDA-approved for T2D.

Typical Cigna/Express Scripts PA criteria for a T2D GLP-1: a confirmed T2D diagnosis (ICD-10 E11.x), a documented A1C measurement, usually a trial of metformin (or documented metformin intolerance/contraindication), and prescriber documentation of treatment goals. The diabetes indication is not subject to the AOM-exclusion problem because the drug is being used for diabetes, not weight loss. For drug-level detail, see our semaglutide drug page and tirzepatide drug page.

GLP-1 coverage for chronic weight management (employer add-on, strict PA)

This is where Cigna becomes restrictive. The three FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg, indications: chronic weight management in adults + pediatric patients aged 12+ with obesity, plus cardiovascular risk reduction in adults with established CVD + overweight/obesity, per DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b^[6]), Zepbound (tirzepatide, indications: chronic weight management + moderate-to-severe OSA in adults with obesity, per DailyMed SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b^[7]), and Saxenda (liraglutide 3.0 mg) — are excluded from the base Express Scripts formulary and covered only when the employer buys AOM coverage.^[4]

When the plan does include AOM coverage, Cigna's published coverage policy applies a multi-part prior-authorization gate. The Cigna/FEP weight-loss GLP-1 policy (effective January 1, 2026) requires, with documentation, all of the following for initial approval:^[1]

1. Age 18 or older.
2. BMI ≥ 30 kg/m², OR BMI ≥ 27 kg/m² with either established cardiovascular disease or at least one weight-related comorbidity (type 2 diabetes, dyslipidemia, or hypertension).
3. Inadequate treatment response, intolerance, or contraindication to at least TWO oral weight-management medications (e.g., phentermine, Qsymia, diethylpropion, benzphetamine).
4. Participation in a comprehensive weight-management program (e.g., Teladoc or another structured weight-loss program with behavioral, dietary, and physical-activity components).
5. No dual therapy with another GLP-1 receptor agonist or another PA weight-loss medication.
6. Trial of the plan's preferred product(s) first (step therapy), unless a valid medical exception applies.

Quantity limit: the policy caps Zepbound at 12 single-dose pens per 84 days, with an initial approval duration of 6 months.^[1] Reauthorization requires documented loss of at least 5% of baseline body weight (or maintenance of that initial 5% loss) plus continued participation in a weight-management program; renewal is then approved for 12 months.^[1] For the underlying weight-loss magnitudes that anchor those PA thresholds, compare provider options on our best semaglutide providers and best tirzepatide providers pages.

The Evernorth $200/month cap and EncircleRx

In May 2025, Evernorth launched a benefit option that caps member out-of-pocket cost for Wegovy and Zepbound at $200 per month for participating employer plans — with the added feature that the amount counts toward the member's annual deductible. The program is built on direct manufacturer agreements with Novo Nordisk and Eli Lilly, and fills route through a broad retail-pharmacy network or Evernorth's EnGuide home-delivery pharmacy, with a simplified, automated prior-authorization step.^[5]

This sits inside Evernorth's broader EncircleRx weight-management program, which the company reports has grown to more than 9 million enrolled lives since its early-2024 launch and is positioned as a financial-guardrail + clinical-oversight wrapper around GLP-1 access.^[5] Two caveats for members:

• The cap is an employer option, not a default. Your employer must have selected the weight-management benefit option for you to get the $200 ceiling. If they didn't buy AOM coverage at all, there is no cap because there is no coverage.
• The cap does not remove the PA gate. You still have to clear the BMI, oral-drug-trial, weight-program, and step-therapy requirements above before the $200 cap applies.

Cigna Medicare — federal Part D exclusion (and the new exceptions)

Cigna offers Medicare Advantage (MA-PD) and standalone Part D (PDP) plans. Like every Medicare Part D plan in the country, they operate under Social Security Act §1860D-2(e)(2)(A), which explicitly excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.^[2] This is a federal statutory exclusion — a Cigna Medicare plan cannot cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications no matter how much medical necessity is documented.

Three pathways let Cigna Medicare members access an otherwise-excluded GLP-1:

• Ozempic / Mounjaro / Trulicity for T2D. T2D is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.
• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this distinct indication on December 20, 2024; because OSA is not weight loss, the Part D exclusion does not block coverage. The Zepbound label (SetID 487cd7e7-434c-4925-99fa-aa80b1cc776b^[7]) lists OSA in adults with obesity as a separately FDA-approved indication; the SURMOUNT-OSA trial is the underlying evidence base.^[8]
• Wegovy for cardiovascular risk reduction. Wegovy's second FDA-approved indication is reducing the risk of major adverse cardiovascular events in adults with established CVD and overweight/obesity (DailyMed SetID ee06186f-2aa3-4990-a760-757579d8f77b^[6]). As a non-weight-loss indication, this is coverable on Medicare Part D, though formulary placement and PA vary by plan.

The Medicare GLP-1 Bridge (July 1, 2026 – December 31, 2027)

A major 2026 development for Cigna Medicare members: CMS launched the Medicare GLP-1 Bridge, a time-limited demonstration that lets eligible Part D beneficiaries get certain GLP-1 drugs for weight management at a flat $50/month copay, running July 1, 2026 through December 31, 2027.^[9] Key mechanics:

• $50 flat copay regardless of Part D benefit phase. The $50 does NOT count toward the Part D deductible or the annual out-of-pocket maximum.^[9]
• Part D plans do not have to opt in. Beneficiaries can access the eligible GLP-1 even if their Cigna Part D plan does not participate, and plan sponsors carry no risk for the drug under the demonstration.^[9]
• Clinical eligibility is gated on BMI thresholds plus qualifying conditions (e.g., heart failure, hypertension, chronic kidney disease, prediabetes, or a history of cardiovascular events); a provider must submit a PA and a prescription for an eligible weight-management use.^[9]
• No member action required to be eligible — beneficiaries do not have to register or opt in.^[9]

If you have a Cigna Medicare plan and were told weight-loss GLP-1s are excluded, the Bridge demonstration may now give you a $50/month path — confirm eligibility against the CMS clinical criteria with your prescriber.

How to find out if YOUR Cigna plan covers Wegovy or Zepbound

Four reliable ways, in order from fastest to most authoritative:

1. express-scripts.com (or the Cigna member portal) drug-coverage search. Sign in with your plan, search “Wegovy” or “Zepbound,” and the result indicates tier, PA status, step therapy, and quantity limits for your specific formulary. This is the canonical source for your plan.^[4]
2. Phone Express Scripts / Cigna member services. The number is on the back of your card. Ask specifically: “Does my plan include anti-obesity-medication coverage? Is Wegovy/Zepbound covered for weight loss, what tier, and what are the PA and step-therapy requirements?”
3. Ask HR or your benefits administrator whether AOM coverage was purchased. Because weight-loss-drug coverage is an employer add-on, HR can confirm whether your group bought it — and whether you're on the Evernorth $200-cap option.
4. Request the Summary Plan Description (SPD) / Evidence of Coverage (EOC). AOM exclusions, if present, are listed in the excluded-benefits section. For Medicare plans, check the EOC and the formulary's excluded-drugs list.

Prior authorization and appeal pathway (through Express Scripts)

Because the benefit runs through Express Scripts, the PA and appeal machinery is the PBM's, not Cigna's medical side. The typical flow:

1. Your prescriber submits a prior-authorization request to Express Scripts (often via the Express Scripts/CoverMyMeds electronic PA portal) documenting BMI, comorbidities, the two prior oral-weight-loss-drug trials, and the weight-management-program enrollment.^[1]
2. Express Scripts adjudicates against the coverage policy; specialty fills may route through Accredo or EnGuide home delivery. Standard PA decisions are typically returned within a few business days; expedited review is available for urgent cases.
3. If denied, a first-level internal appeal is filed with Express Scripts/Cigna within the timeframe on the denial notice; the prescriber can add clinical documentation or a step-therapy exception request.
4. If upheld, a second-level internal appeal follows, then an external review by an independent review organization. For fully-insured plans the external review routes through the state insurance regulator; for ERISA self-funded employer plans it follows the federal ERISA framework and ultimately the U.S. Department of Labor.

For the operational playbook on appealing dropped coverage across any payer, see our GLP-1 insurance dropped-coverage appeal playbook . For side effects to document during an appeal, see our GLP-1 side-effect questions hub .

If Cigna denies or excludes — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Check the Medicare GLP-1 Bridge (Medicare members). Starting July 1, 2026, eligible Part D members can get a covered GLP-1 for weight management at $50/month even if their Cigna Part D plan doesn't participate.^[9]
• The Zepbound OSA pathway (Medicare or commercial). With a moderate-to-severe OSA diagnosis (AHI ≥ 15 on polysomnography), your prescriber can submit a Zepbound PA for the OSA indication rather than weight loss — the Part D exclusion does not apply.^[7]
• Wegovy for cardiovascular risk reduction. With established CVD plus overweight/obesity, your prescriber can submit a Wegovy PA for the CV-risk-reduction indication — a non-weight-loss indication.^[6]
• Cash-pay oral GLP-1s and self-pay vials. 2026 launches of the Wegovy pill and Lilly's oral Foundayo start near $149/month for the lowest dose; LillyDirect Self Pay vials run roughly $299–$699/month by dose.^[3] Compounded tirzepatide/semaglutide via verified 503A telehealth is another lower-cost route, though it is not brand Wegovy/Zepbound and quality varies.
• Switch payers or push HR at open enrollment. Because AOM coverage is an employer decision, the realistic lever is asking HR to add the Evernorth weight-management benefit, or switching plans. For how a structurally different payer handles this, compare our Kaiser Permanente weight-loss coverage review , and see the broader insurance coverage hub .

Verdict — what most Cigna members should expect

For the median Cigna member asking does Cigna cover weight loss drugs: the answer splits by indication and by employer plan design, not by a single national yes-or-no.

1. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus): generally YES with Express Scripts prior authorization confirming the T2D diagnosis.
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): excluded from the standard Express Scripts formulary — covered ONLY if your employer bought AOM coverage, and then only after a strict PA gate (BMI, two oral-drug trials, weight-management program, step therapy).^[1]
3. Cigna Medicare members: NO for weight-loss-only; YES for Zepbound OSA and Wegovy CV-risk-reduction; and the new Medicare GLP-1 Bridge gives eligible members a $50/month weight-management path starting July 1, 2026.^[9]
4. If covered: the Evernorth $200/month cap (when the employer selects it) is the cheapest commercial path, with the amount counting toward the deductible.^[5]

The headline caveat: on June 1, 2026, Cigna told its own employees it will stop covering weight-loss GLP-1s in the Cigna Group Medical Plan effective July 1, 2026, citing falling cash prices for newer oral options — while stressing the change does not affect external client plans or the diabetes indication.^[3] It is a useful read on where large self-funded employers may move, and a reminder that AOM coverage is a discretionary, revisable employer benefit, not a guaranteed one.

Further reading

• Does Kaiser Permanente cover weight loss drugs?
• Top GLP-1 insurance-coverage questions on Reddit, answered
• GLP-1 contraindications cheat sheet